Lonza Group, a Swiss chemicals and biotechnology company, will acquire Capsugel for $5.5 billion, reports Reuters.
Here are four things to know about the deal.
1. Capsugel, based in Morristown, N.J., manufactures empty drug capsules, along with several other drug delivery systems.
3. Lonza's shares fell by more than 7 percent to 157 Swiss francs ($154) per share upon news of the acquisition, which cost the Swiss company more than 60 percent of its market value.
4. The deal is expected to close in the second quarter of 2017.
More articles on supply chain:
FDA approves Pfitzer's eczema treatment
5 latest FDA approvals
7 supply chain lessons from auto and retail industries